A World Health Organization panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.
The panel on Thursday strongly recommended Lilly's baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir's antibody therapy for non-severe patients at the highest risk of hospitalisation. The WHO experts noted that the effectiveness of monoclonal antibody treatments - lab-generated compounds that mimic the body's natural defences - against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.
Similar News:You can also read news stories similar to this one that we have collected from other news sources.